Marksans Pharma shares jumped as much as 14% on Wednesday, touching a fresh 52 week high of ₹320 after Q1 profit nearly tripled year on year.

Consolidated net profit for Q1FY27 nearly tripled to ₹157.17 crore, up from ₹58.32 crore in the same quarter last year. Revenue climbed 35.6% to ₹840.80 crore from ₹620 crore.

EBITDA more than doubled to ₹213.04 crore, and the operating margin expanded sharply to 25.3% from 16.2% a year earlier.

The standout performer was the UK and Europe formulation business, which posted its highest ever quarterly revenue of ₹356 crore, up nearly 75% year on year.

The company credited new product launches, market share gains in the UK and a healthy order pipeline for the jump.

Its Netherlands based unit, QliniQ, also chipped in ₹44 crore of revenue during the quarter as the European push gathers pace.

The US and North America business, which makes up close to 45% of overall revenue, grew a more modest 15.1% to ₹377 crore.

Sales from Australia and New Zealand rose 53.7% to ₹88 crore, while the Rest of World segment slipped 36.8% due to delayed shipments to the Middle East, though it did improve 6% from the previous quarter.

The stock has had a strong run over the past year, more than doubling from its 52 week low of ₹155 touched in March.

That builds on a solid FY26, when Marksans posted a 9.8% rise in annual net profit to about ₹420 crore, with revenue up 12.5% to roughly ₹2,951 crore.

Managing Director Mark Saldanha called it a strong start to the financial year, and pointed to the company’s cash balance, which crossed ₹1,000 crore for the first time to reach ₹1,058 crore, even after its recent acquisitions of QliniQ and ABCnow.

He said this gives Marksans room to keep investing in organic growth while staying open to selective acquisitions.

At 14:08 pm, the stock was trading at ₹318.10 on the NSE, up 14.03% for the day.

Ready to invest like a pro? Tradz by EquityPandit app equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz by EquityPandit app and gain access to daily stock lists and insightful market analysis and much more!